Request Demo
Recent blog posts
Latest Hotspot
8 min read
Kearns-Sayre syndrome Indication Strategy Report 2026: Mitochondrial DNA, Trials and Deals
24 July 2026
2026 Kearns-Sayre syndrome strategy: epidemiology, Mitochondrial DNA biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
LCAT deficiency Indication Strategy Report 2026: LCAT, Trials and Deals
24 July 2026
2026 LCAT deficiency strategy: epidemiology, LCAT biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Latest Hotspot
8 min read
Tangier disease Indication Strategy Report 2026: ABCA1, Trials and Deals
24 July 2026
2026 Tangier disease strategy: epidemiology, ABCA1 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Latest Hotspot
8 min read
Abetalipoproteinemia Indication Strategy Report 2026: MTTP, Trials and Deals
24 July 2026
2026 Abetalipoproteinemia strategy: epidemiology, MTTP biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…
Latest Hotspot
8 min read
Cerebrotendinous xanthomatosis Indication Strategy Report 2026: CYP27A1, Trials and Deals
24 July 2026
2026 Cerebrotendinous xanthomatosis strategy: epidemiology, CYP27A1 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Lysinuric protein intolerance Indication Strategy Report 2026: SLC7A7, Trials and Deals
24 July 2026
2026 Lysinuric protein intolerance strategy: epidemiology, SLC7A7 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Cystinuria Indication Strategy Report 2026: SLC3A1, Trials and Deals
24 July 2026
2026 Cystinuria strategy: epidemiology, SLC3A1 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Latest Hotspot
8 min read
Methylglutaconic aciduria Indication Strategy Report 2026: TAZ, Trials and Deals
24 July 2026
2026 Methylglutaconic aciduria strategy: epidemiology, TAZ biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Hartnup disease Indication Strategy Report 2026: SLC6A19, Trials and Deals
24 July 2026
2026 Hartnup disease strategy: epidemiology, SLC6A19 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Latest Hotspot
8 min read
3-methylcrotonyl-CoA carboxylase deficiency Indication Strategy Report 2026: MCCC1, Trials and Deals
24 July 2026
2026 3-methylcrotonyl-CoA carboxylase deficiency strategy: epidemiology, MCCC1 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
HMG-CoA lyase deficiency Indication Strategy Report 2026: HMGCL, Trials and Deals
24 July 2026
2026 HMG-CoA lyase deficiency strategy: epidemiology, HMGCL biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Holocarboxylase synthetase deficiency Indication Strategy Report 2026: HLCS, Trials and Deals
24 July 2026
2026 Holocarboxylase synthetase deficiency strategy: epidemiology, HLCS biology, clinical competition, recent deals, unmet need and market attractiveness.